Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label Study of the Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With the Atypical Antipsychotic Drug, Olanzapine

Next Previous
X
Search
Trial Profile

A Randomized, Open-Label Study of the Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With the Atypical Antipsychotic Drug, Olanzapine

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RDX-002 (Primary)
  • Indications Obesity
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Response Pharmaceuticals

    • Most Recent Events

    • 17 Oct 2024 According to Response pharmaceuticals media release, company will be presenting the results from proof-of-concept study of RDX-002 in antipsychotic induced weight gain at Obesity Week 2024 in San Antonio on Nov 4th, as per this link; https://obesityweek.org for program and full details.
    • 23 Apr 2024 Topline Results presented in the Response pharmaceuticals Media Release.
    • 23 Apr 2024 According to Response pharmaceuticals media release, detailed data set from the study will be presented at an upcoming medical conference and in a scientific publication.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top